The primary purpose of the upcoming study is to confirm positive clinical results published in 2002, which demonstrated that Celadrin oral capsules improved range of motion and overall function in knee osteoarthritis patients.
The 60-day study, a double-blind, placebo-controlled trial expected to be completed this summer, will involve 84 patients currently diagnosed with moderate to severe knee osteoarthritis. The patients will be studied at two locations in the US operated by private clinical trials facility Medicus Research.
Celadrin is an all-natural proprietary Imagenetix compound that works by supporting the lubrication of joints and enhancing fluids that cushion bones and joints. Clinical research published recently in both the Journal of Rheumatology and the Journal of Strength & Conditioning Research demonstrated that knee osteoarthritis patients using topical administration of Celadrin cream had significant improvement in knee range of motion, balance, mobility and overall knee function, without side effects.